5-Amino-1MQ Peptide

5-Amino-1MQ Molecular Structure & Chemical Properties

5-Amino-1MQ (5-amino-1-methylquinolinium) represents a novel class of small molecule metabolic modulators that has generated significant research interest since its characterization in 2017. As a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), this synthetic compound has been investigated in over 30 published preclinical studies examining its effects on metabolic regulation, adipose tissue dynamics, and muscle regeneration. Unlike traditional weight management compounds that primarily suppress appetite or increase thermogenesis, 5-Amino-1MQ operates through a unique mechanism targeting cellular energy metabolism at the enzymatic level, offering a fundamentally different approach to metabolic research.

Chemical Structure

diagram showing quinolinium scaffold (Source: PubChem)

Technical Specifications

The compound’s quinolinium scaffold with a primary amine substitution at the 5-position provides high membrane permeability through both passive and active transport mechanisms, allowing effective cellular penetration without significant efflux. This structural feature distinguishes 5-Amino-1MQ peptide from earlier NNMT inhibitors that exhibited poor bioavailability.

5-Amino-1MQ Mechanism of Action

5-Amino-1MQ exerts its biological effects primarily through potent and selective inhibition of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that has emerged as a critical regulator of cellular metabolism and energy homeostasis. The compound functions as a substrate-site targeting inhibitor with an IC50 of approximately 1.2 micromolar, demonstrating over 1000-fold selectivity against related methyltransferases and NAD+ salvage pathway enzymes.

Primary Cellular Pathways

NNMT Inhibition and NAD+ Enhancement

Research has demonstrated that 5-Amino-1MQ competitively binds to the NNMT substrate-binding site, preventing the methylation of nicotinamide (NAM) to 1-methylnicotinamide (1-MNA)[1]. This inhibition produces several critical metabolic effects:

• Increased intracellular NAD+ levels (up to 2-fold elevation in adipocytes)
• Preservation of nicotinamide for NAD+ biosynthesis via salvage pathways
• Enhanced mitochondrial function through improved electron transport chain activity
• Activation of NAD+-dependent enzymes including sirtuins

Studies in differentiated adipocytes showed that 5-Amino-1MQ treatment (30 micromolar) significantly reduced intracellular 1-MNA levels while increasing NAD+ concentrations[2].

SIRT1 Activation and Metabolic Regulation

The increase in cellular NAD+ levels directly activates sirtuin-1 (SIRT1), often termed the “longevity gene” due to its role in metabolic regulation and cellular stress resistance[3]:

• Deacetylation of metabolic regulatory proteins
• Enhanced mitochondrial biogenesis through PGC-1alpha activation
• Improved insulin sensitivity and glucose metabolism
• Regulation of lipid metabolism and fat oxidation

SAM-Dependent Methylation Modulation

NNMT inhibition also affects the methionine cycle by reducing consumption of S-adenosylmethionine (SAM), the universal methyl donor[4]:

• Increased intracellular SAM availability for essential methylation reactions
• Potential effects on epigenetic modifications through histone methylation
• Modulation of polyamine synthesis pathways
• Regulation of cellular methylation capacity

Adipocyte-Specific Effects

In adipose tissue, where NNMT expression is particularly elevated in obesity, 5-Amino-1MQ demonstrates pronounced effects on fat cell metabolism[5]:

• Suppression of lipogenesis (50-70% reduction at therapeutic concentrations)
• Reduction in adipocyte size and volume
• Decreased expression of lipogenic enzymes
• Enhanced lipolytic activity and fatty acid oxidation

Muscle Stem Cell Activation

Recent investigations have revealed that NNMT inhibition activates quiescent muscle satellite cells (muSCs), promoting muscle regeneration[6]:

• Enhanced muSC proliferation and differentiation
• Improved myofiber regeneration following injury
• Increased muscle protein synthesis
• Restoration of regenerative capacity in aged muscle

5-Amino-1MQ Research Applications & Key Findings

Metabolic Research and Obesity Models

Diet-Induced Obesity Studies

Extensive research in rodent obesity models has examined 5-Amino-1MQ’s effects on body composition and metabolic parameters. In a landmark 11-day study using diet-induced obese (DIO) C57BL/6 mice, systemic administration of 5-Amino-1MQ peptide (20 mg/kg three times daily) produced remarkable results[1]:

• 5.1% reduction in body weight from baseline (while vehicle controls gained 1.4%)
• 30-35% decrease in white adipose tissue mass
• 40% reduction in adipocyte volume with significant decreases in cell size
• 30% lower total plasma cholesterol levels compared to untreated obese controls
• No changes in food intake, indicating metabolic rather than appetite-suppressing effects

Notably, these effects occurred without observable adverse effects or changes in feeding behavior, suggesting NNMT inhibition increases energy expenditure rather than reducing caloric intake.

Combined Dietary Intervention Studies

Research combining 5-Amino-1MQ treatment with dietary modification demonstrated synergistic effects on metabolic normalization[7]. When DIO mice were transitioned from high-fat diet to lean diet with concurrent NNMT inhibitor treatment:

• 29.3% reduction in fat mass (10-fold greater than diet switch alone)
• Rapid normalization of body composition to age-matched lean controls
• Establishment of distinct gut microbiome profile with increased Lactobacillus abundance
• Enhanced metabolic benefits compared to dietary intervention alone

Glucose Metabolism and Insulin Sensitivity

Studies evaluating metabolic parameters in DIO models showed that 5-Amino-1MQ treatment produced[8]:

• Improved oral glucose tolerance
• Enhanced insulin sensitivity with reduced hyperinsulinemia
• Normalized fasting blood glucose levels
• Dose-dependent improvements in glucose homeostasis

Muscle Regeneration Research

Aged Muscle Stem Cell Activation

Groundbreaking research in aged mouse models demonstrated that NNMT inhibition significantly enhances muscle stem cell function and regenerative capacity[6]. In 24-month-old mice treated with 5-Amino-1MQ following muscle injury:

• Enhanced muSC proliferation and activation in aged muscle
• Improved myofiber cross-sectional area post-injury
• 70% increase in peak muscle torque of injured muscles compared to aged controls
• Restoration of regenerative capacity approaching that of young muscle

These findings suggest NNMT inhibition may counteract sarcopenia-associated decline in muscle repair mechanisms.

Exercise and Muscle Function Studies

A 2024 study investigated the interaction between NNMT inhibition and exercise training in aged mice[9]. Remarkably, the research revealed:

• 40% greater grip strength in sedentary aged mice treated with 5-Amino-1MQ compared to untreated controls
• 20% increase in grip strength from exercise alone
• 60% combined increase when NNMT inhibition was paired with rigorous exercise training
• Additive effects suggesting independent mechanisms of action
• Evidence of reduced muscle recovery time following exercise

The data indicate that NNMT inhibition mimics and amplifies exercise-mediated improvements in muscle function, offering potential therapeutic applications for age-related muscle decline.

Liver and Metabolic Health Research

Hepatic Steatosis Studies

Research in obesity models has examined 5-Amino-1MQ’s effects on liver pathology[10]:

• Attenuated hepatic steatosis with reduced liver triglyceride accumulation
• Decreased liver weight and size in treated DIO mice
• Reduced macrophage infiltration and inflammatory markers
• Normalized circulating liver enzymes (ALT, AST)
• Improvements in overall hepatic metabolic function

Cardiovascular and Lipid Research

Investigations into cardiovascular risk factors demonstrated[1]:

• Significant reductions in total plasma cholesterol
• Normalization of lipid profiles in obese models
• Potential improvements in metabolic syndrome parameters
• Effects on cholesterol independent of weight loss magnitude

Pharmacokinetic Characterization

Bioavailability and Absorption Studies

LC-MS/MS characterization in rat models revealed important pharmacokinetic properties[11]:

• Oral bioavailability of 38.4% (unusually high for a charged quaternary compound)
• Rapid absorption with peak plasma concentrations within 1-2 hours
• High tissue distribution to metabolically active organs (adipose, muscle, liver)
• Effective systemic exposure following subcutaneous administration

5-Amino-1MQ Pharmacokinetics & Metabolism

Absorption & Distribution

5-Amino-1MQ exhibits favorable absorption characteristics despite being a positively charged quaternary ammonium compound. Pharmacokinetic studies in Sprague-Dawley rats demonstrated[11]:

• Oral bioavailability of 38.4% following oral administration
• Mean maximum plasma concentration (Cmax) of 2252 ng/mL after oral dosing
• Rapid and substantial absorption following subcutaneous injection
• High passive membrane permeability (PAMPA assay: >150 nm/s)
• Active transport mechanisms contributing to cellular uptake

Distribution studies revealed effective tissue penetration to metabolically relevant organs, with significant concentrations measured in white adipose tissue, skeletal muscle, and liver following systemic administration. The compound demonstrates minimal efflux, allowing sustained intracellular concentrations.

Metabolism & Elimination

The metabolic fate of 5-Amino-1MQ has been partially characterized in rodent models[11]:

• Terminal elimination half-life of 3.8 hours following intravenous administration
• Terminal elimination half-life of 6.9 hours following oral administration
• Rapid plasma clearance following distribution phase
• Metabolic pathways not fully elucidated but likely involving oxidative metabolism
• No evidence of accumulation with repeated daily dosing

A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-life (under 7 hours), biological effects on metabolism and body composition persist for days after treatment cessation, suggesting either active metabolite formation, tissue retention, or persistent downstream signaling effects.

Excretion Pathways

Limited data on elimination routes indicates[11]:

• Primary renal excretion likely for parent compound and metabolites
• Hepatic metabolism may contribute to clearance
• No significant accumulation detected in 28-day repeated dose studies
• Excretion kinetics in humans remain unstudied

The compound’s high water solubility (>100 mg/mL) likely facilitates renal elimination, though detailed excretion balance studies have not been published.

5-Amino-1MQ Research Protocols & Administration

Dosing in Published Research

Research investigations have employed various 5-Amino-1MQ doses depending on model and objectives:

• Mouse obesity studies: 20 mg/kg three times daily (total ~60 mg/kg/day) subcutaneous injection for 11-45 days
• Rat pharmacokinetic studies: 5-20 mg/kg single doses (oral and intravenous routes)
• Mouse muscle regeneration studies: 5-10 mg/kg twice daily subcutaneous injection for 2-4 weeks
• Aged mouse exercise studies: 10 mg/kg once daily subcutaneous injection for 8 weeks
• Cell culture studies: 1-60 micromolar concentrations for 24-72 hours

Important: These are experimental doses used in animal research studies and cannot be extrapolated to other species due to significant differences in NNMT expression patterns, enzyme kinetics, metabolic clearance rates, tissue distribution, and receptor density. Species-specific pharmacological factors profoundly influence both efficacy and safety profiles. Human dosing, if ever established, would require dedicated clinical trials to determine appropriate parameters.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical models:

• Subcutaneous injection – Most common route in rodent studies; provides reliable systemic delivery and sustained plasma levels
• Oral administration – Demonstrated effective absorption with 38% bioavailability in rats; used in pharmacokinetic characterization
• Intravenous injection – Employed primarily for pharmacokinetic studies and bioavailability reference
• Intraperitoneal injection – Used in some metabolic studies for systemic delivery

Common Model Organisms

5-Amino-1MQ research has been conducted across multiple experimental systems:

• Mice – Primary research model (C57BL/6 strain predominant); used for obesity, muscle, and metabolic studies; aged mice (22-24 months) for sarcopenia research
• Rats – Sprague-Dawley strain used for pharmacokinetic characterization and absorption studies
• Cell culture systems – 3T3-L1 pre-adipocytes and differentiated adipocytes for mechanistic studies; primary murine muscle satellite cells for regeneration research; HeLa cells for cancer-related investigations

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite accumulating preclinical evidence, 5-Amino-1MQ faces substantial translational barriers that significantly limit its research utility and prevent any clinical application.

Lack of Human Clinical Data

The most significant limitation is the complete absence of human clinical trials:

• No peer-reviewed human studies exist in scientific literature
• No Phase I safety trials registered or published
• No Phase II efficacy studies initiated
• Human pharmacokinetics completely uncharacterized
• Optimal human dosing unknown and cannot be predicted from animal data
• Long-term safety profile in humans completely unstudied
• No data on drug interactions or contraindications

While some wellness clinics have reportedly administered 5-Amino-1MQ to clients, no systematic data collection or safety monitoring has been published, representing uncontrolled use of an investigational compound.

Mechanistic Understanding Gaps

Fundamental aspects of 5-Amino-1MQ’s mechanism require clarification:

• Tissue-specific effects of NNMT inhibition incompletely understood
• Whether benefits derive solely from NAD+ elevation or involve additional pathways remains unclear
• Relationship between short plasma half-life and prolonged biological effects unexplained
• Potential effects on non-target tissues with NNMT expression unstudied
• Long-term consequences of sustained NNMT inhibition unknown

Long-Term Safety Considerations

Critical safety questions remain unanswered even in preclinical models:

• Chronic effects beyond 8 weeks unstudied in any species
• Potential impact on methylation-dependent processes with extended use unknown
• Effects on cancer cell metabolism raise theoretical concerns requiring investigation
• Reproductive and developmental toxicity not assessed
• Genotoxicity studies show no mutagenic effects in bacterial and cell assays, but comprehensive safety evaluation incomplete
• Unknown interactions with common medications or dietary supplements

Regulatory & Competitive Sport Status

FDA Position

5-Amino-1MQ has not received FDA approval and exists in regulatory limbo:

• Not approved for any human or veterinary indication
• Not recognized as Generally Recognized as Safe (GRAS)
• Not approved for compounding in human medications
• Classified as an investigational new drug substance
• Not legally marketed as a dietary supplement (does not meet supplement criteria)
• Available only as “research chemical” from non-regulated suppliers

The FDA has not issued specific guidance on 5-Amino-1MQ but includes similar experimental metabolic modulators under scrutiny for unapproved marketing claims.

WADA Prohibition

The World Anti-Doping Agency’s regulations affect competitive athletes:

• Falls under Section S0 (Non-Approved Substances) of the Prohibited List
• Prohibited at all times (in and out of competition) for athletes subject to WADA Code
• No governmental regulatory authority has approved 5-Amino-1MQ for therapeutic use
• No Therapeutic Use Exemptions (TUEs) available
• Detection methods under development for anti-doping testing

Athletes competing under WADA-compliant organizations should assume 5-Amino-1MQ is prohibited and could result in anti-doping violations.

Research Classification: 5-Amino-1MQ is available only for laboratory research use under appropriate institutional oversight. It is not intended for human consumption, medical diagnosis, treatment or prevention of disease, or veterinary applications. All research must be conducted under appropriate ethical review board approval and regulatory compliance.

References

1. Neelakantan, H., Vance, V., Wetzel, M.D., Wang, H.L., McHardy, S.F., Finnerty, C.C., Hommel, J.D., & Watowich, S.J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141-152. PubMed
   
2. Neelakantan, H., Wang, H.Y., Vance, V., Hommel, J.D., McHardy, S.F., & Watowich, S.J. (2017). Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. Journal of Medicinal Chemistry, 60(11), 5015-5028. PubMed
   
3. Hong, S., Moreno-Navarrete, J.M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., Lee, Y., Asara, J.M., Fernandez-Real, J.M., Maratos-Flier, E., & Pissios, P. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 21(8), 887-894. PubMed
   
4. Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T., Pirinen, E., Pulinilkunnil, T.C., Gong, F., Wang, Y.C., Cen, Y., Sauve, A.A., Asara, J.M., Peroni, O.D., Monia, B.P., Bhanot, S., Alhonen, L., Puigserver, P., & Kahn, B.B. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262. PubMed
   
5. Neelakantan, H., Vance, V., Wetzel, M.D., Wang, H.L., McHardy, S.F., Finnerty, C.C., Hommel, J.D., & Watowich, S.J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141-152. PubMed
   
6. Neelakantan, H., Brightwell, C.R., Graber, T.G., Maroto, R., Wang, H.L., McHardy, S.F., Papaconstantinou, J., Fry, C.S., & Watowich, S.J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481-492. PubMed
   
7. Dimet-Wiley, A., Wu, Q., Wiley, J.T., Eswar, A., Neelakantan, H., Savidge, T., & Watowich, S. (2022). Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports, 12(1), 484. PubMed
   
8. Babula, J.J., Bui, D., Stevenson, H.L., Watowich, S.J., & Neelakantan, H. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism, 26(11), 5272-5282. PubMed
   
9. Dimet-Wiley, A.L., Latham, C.M., Brightwell, C.R., Neelakantan, H., Keeble, A.R., Thomas, N.T., Noehren, H., Fry, C.S., & Watowich, S.J. (2024). Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports, 14(1), 15554. PubMed
   
10. Babula, J.J., Bui, D., Stevenson, H.L., Watowich, S.J., & Neelakantan, H. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism, 26(11), 5272-5282. PubMed
    
11. Awosemo, O., Neelakantan, H., Watowich, S.J., Ma, J., Wu, L., Chow, D.S., & Liang, D. (2021). Development and validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis, 203, 114212. PubMed
    
12. Lee, Y.S., Loh, W.L., Yang, J.W., Ye, X., Lee, G.H., & Yeo, W.K. (2021). Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells. IUBMB Life, 73(4), 643-654. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. 5-Amino-1MQ is intended for laboratory research use only.